Evicenter
MarkdownMedical informationP&T meetings
Vonaprument (ANX007)

Geographic atrophy secondary to age-related macular degeneration

Launch
Not announced
Last updated
167 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Complement c3 inhibitors

11 evidence topics · 6 sources

OAKS and DERBY: GA lesion growth from baseline to month 24
Study and groupRate of GA lesion area growth (mm2), slope (SE)Difference (95% CI) in slope from sham pooledPercent difference from sham pooled
OAKS, pegcetacoplan monthly“3.11 (0.148)”“−0.87”“(−1.27 to −0.47)”“−21.9%”
OAKS, pegcetacoplan every other month“3.26 (0.134)”“−0.72”“(−1.10 to −0.33)”“−18.1%”
OAKS, sham pooled“3.98 (0.143)”“NA”“NA”
DERBY, pegcetacoplan monthly“3.28 (0.125)”“−0.73”“(−1.14 to −0.31)”“−18.1%”
DERBY, pegcetacoplan every other month“3.31 (0.129)”“−0.70”“(−1.11 to −0.28)”“−17.4%”
DERBY, sham pooled“4.00 (0.169)”“NA”“NA”